Sanofi-Aventis To Expand China’s Flu Vaccine Market
This article was originally published in PharmAsia News
Once its Shenzhen flu vaccine production plant goes into operation in 2012, Sanofi-Aventis plans to sell 15 million doses of seasonal flu vaccine annually in China. A company official reveals that the estimate is based on projected global need of 1.3 billion vaccine doses by 2016, with China being one of the major markets. However, the country's inoculation rate stands at a mere 1.5 percent compared with 20 to 40 percent in Europe and North America. Moreover, over 60 percent of China's users opt for low-cost domestic products. Sanofi thus needs to decrease its production cost. Analysts note that without a consortium to standardize vaccine production and management locally, replicated and wasted efforts are hampering promotion and widespread usage. (Click here for more - Chinese Language)
You may also be interested in...
Sanofi Pasteur is intensifying efforts to build a vaccine production base in Shenzhen (PharmAsia News, Oct. 20, 2008). The first phase of construction on the facility was completed in October 2008, and the entire project is scheduled to be completed by 2012. The facility will produce mainly influenza vaccines for influenza A and B type H1N1 and H3N2, with an annual output for 25 million people. To facilitate the project, Shenzhen municipal government will handle all issues of certification and licenses as well as business consulting by the end of December. (Click here for more - Chinese Language)
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.